VCYT News & Events

Veracyte announced that its TrueMRD Monitoring Test has received coverage from the Centers for Medicare & Medicaid Services', CMS, Molecular Diagnostics Services Program for patients with muscle-invasive bladder cancer, MIBC. The TrueMRD Test is covered for recurrence monitoring following definitive treatment with curative intent in patients with MIBC. It will be available for clinicians to order on June 1, 2026, marking the commercial launch of Veracyte's first molecular residual disease, MRD, offering and the only commercially available truly whole-genome MRD test to come to market, expanding the company's reach into cancer recurrence monitoring.

Reports Q1 revenue $139.1M, consensus $144.1M. "We had a strong start to the year, with Decipher and Afirma volume growth surpassing expectations and exceeding our profitability targets," said Marc Stapley, Veracyte's CEO. "Our growing clinical evidence continues to set us apart, and this quarter strengthened it even further. We believe we are approaching an inflection point with the upcoming launches of Prosigna LDT and TrueMRD, two of the most significant new products in our history, creating meaningful opportunities for market expansion in Breast, Bladder and other cancers, alongside continued growth in our Prostate and Thyroid businesses."